An Emergo Group survey of 650 senior medtech executives found that 11% would shrink their workforce to help manage the costs of the 2.3% medical device tax, while about 12% would cut their research and development funding. Meanwhile, more than 40% of respondents said they would deal with the tax by raising product prices.
Survey: Medtech firms could cut jobs, R&D to manage device tax
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||